Profitelligence Profitelligence · Filing Ledger Open JNJ research →

Form 8-K · Current Report · Filed 2025-02-26

Johnson & Johnson Completes Public Offering of New Notes

On February 26, 2025, Johnson & Johnson completed the public offering of €2.0 billion in aggregate principal amount of various notes due between 2029 and 2055 under its Registration Statement on Form S-3.

Filer
Johnson & Johnson JNJ · NYSE
Filed
Accession
0001193125-25-036773
CIK
0000200406
Signal
Medium impactHealthcare

Details

The Company entered into an underwriting agreement with several underwriters for the issuance of these notes.

Items reported

Item 8.01

Other Events

Convertible Notes Offering
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$166.09

Next session

-1.4%

Since filing

+54.3%

Latest close

$256.35

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from JNJ reporting the same item, with the next session's move:

Exhibits (9)

About Johnson & Johnson

Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another JNJ filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts